J I I I I mmmmmmmmmmmmmmmmmmmmmmm ...
Describe in Part IV the organization's procedures for monitoring the use of grant funds in the United States. Yes. No. 
??????????????????????Crizotinib????. ???ALK???????????HGFR?C-Met??. ???????????????????? ... ALK+???B??????????* - ???????????????????. ALK ???????NSCLC ?????????. ??????????????????ALK ??. ??????????????????????. ?1 ??? ?????????? AReport of New Drugs Research ...... ?????. ??78%???????????29%?????. ?????????ALK??????NSCLC?. ?????????[24]???????????. ???????? ... ???,??,???. ???????? - ??????2024?????Q3???????75.5%?????????45.0%????????. 6.93??. ?. ??????2024??????????. PowerPoint ???? - InnoCare?????crizotinib?. ???ALCL ?????????????????????. ??????ALK+ALCL?????????????280 mg/. ?m2·?????????????? ... ??ALK ???????????????comparing pemetrexed/platinum-based chemotherapy with crizotinib, indicate that crizotinib is superior to chemotherapy (ChT) in term of ORR ... Augtyro | EMAUltimately, crizotinib was administrated at a dose of 250 mg twice daily every 3 day dosing for 13 months with maintenance of the anti-tumor effect. ??????EML4-ALK/TP53 ????????????????????????????????????. ??????????ALK?ROS1???????[ ]?. ??????????CAP-GLY????CAP-GLY domain ... ? 98 ? ????????????????????????? ?? ? ?S543. 4?4?JS9?2 ??? ... DP?220 ????????????????????? ... ???????? ?? ????S1064. DP?524 ... Super Visual Formade Print - ??????????????????? ?????? ??????. ??????. ?????????????????????????????????????????????. ????????? ??????????????????????????. ??????????????????????????. ???????????. ??????????? ... ?? ???? ??? - ??????????????????????????????????????. ????????????????????????????????? ...
